ASHP Paxlovid Resources
In July 2022, the Food and Drug Administration (FDA) revised its Emergency Use Authorization (EUA) to authorize pharmacists as prescribers of Paxlovid (Nirmatrelvir/Ritonavir) for the treatment of COVID-19. This resource page serves as a tool for pharmacists implementing Paxlovid prescribing in their practice. ASHP will continue to update this resource page as more information becomes available on implementation of this new prescribing privilege.
Resource Highlights
- ASHP Paxlovid Survey
- ASHP Paxlovid Prescribing Guide
- Considerations for Pharmacist Prescribing Nirmatrelvir with Ritonavir (Paxlovid™)
- FDA Fact Sheet for Healthcare Providers: EUA for Paxlovid
- FDA FAQ on EUA for Paxlovid for Treatment of COVID-19
- FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations
Clinical Resources
- FDA Fact Sheet for Healthcare Providers: EUA for Paxlovid
- AHFS Paxlovid Drug Monograph pdf
- FDA FAQ on EUA for Paxlovid for Treatment of COVID-19
- FDA Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers
- American College of Cardiology: Drug-Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid) and Select Cardiovascular Medications
- University of Liverpool COVID-19 Drug Interactions
- IDSA Point-of-Care Reference
- ISMP Medication Safety Issues with Paxlovid
- NIH Treatment Guidelines for Paxlovid
- CDC Clinical Management Summary for COVID-19 Patients
- CDC COVID-19 Patient Risk Factor Assessment
- Paxlovid for the Treatment of COVID-19: Considerations for People with HIV and Hepatitis C
ADVERTISEMENT
ASHP Advocacy
- ASHP Advocacy Yields Major Win on Nationwide COVID-19 Prescribing Authority
- FDA Revises EUA for Paxlovid; Allows State-Licensed Pharmacists to Prescribe
- ASHP Calls for Removal of Prescribing Barriers for COVID Antivirals
- ASHP Letter to White House COVID-19 Response Coordinator
- Pharmacist Groups Call on Biden Administration to Remove Limits on Prescribing COVID Treatments
